Accordingly, the treatment of CRC patients with the clinically approved VEGF-A-targeting antibody Bevacizumab resulted in a significantly reduced frequency of regulatory T cells in the peripheral blood, and the in vivo administration of a fusion protein consisting of an anti-VEGFR2 antibody and IFNα successfully enhanced the accumulation of CD8+ T cells in a murine colorectal cancer xenograft model [145,146,147,148]. This evidence concerns the gene VEGFA and colorectal cancer.